Objective-DKK3 (dickkopf 3), a 36-kD secreted glycoprotein, has been shown to be involved in the differentiation of partially reprogrammed cells and embryonic stem cells to smooth muscle cells (SMCs), but little is known about its involvement in vascular disease. This study aims to assess the effects of DKK3 on atherosclerotic plaque composition. Approach and Results-In the present study, we used a murine model of atherosclerosis (ApoE −/− ) in conjunction with DKK3 −/− and performed tandem stenosis of the carotid artery to evaluate atherosclerotic plaque development. We found that the absence of DKK3 leads to vulnerable atherosclerotic plaques, because of a reduced number of SMCs and reduced matrix protein deposition, as well as increased hemorrhage and macrophage infiltration. Further in vitro studies revealed that DKK3 can induce differentiation of Sca1 + (stem cells antigen 1) vascular progenitors and fibroblasts into SMCs via activation of the TGF-β (transforming growth factor-β)/ATF6 (activating transcription factor 6) and Wnt signaling pathways. Finally, we assessed the therapeutic potential of DKK3 in mouse and rabbit models and found that DKK3 altered the atherosclerotic plaque content via increasing SMC numbers and reducing vascular inflammation. Conclusions-Cumulatively, we provide the first evidence that DKK3 is a potent SMC differentiation factor, which might have a therapeutic effect in reducing intraplaque hemorrhage related to atherosclerotic plaque phenotype. Visual Overview-An online visual overview is available for this article. We have previously shown that DKK3, a member of the dickkopf family of Wnt inhibitors, 7 is involved in the differentiation of partially induced pluripotent stem cells 8 and embryonic stem cells 9 to SMCs. Consequently, assessing the therapeutic potential of DKK3, possibly through differentiation of stem/progenitor cells to SMCs, deemed crucial. Hence, in this study, we used the aforementioned animal model in conjunction with DKK3 −/− mice and found that DKK3 −/− ApoE −/− mice presented with vulnerable plaques. In addition, using in vitro differentiation protocols, we found that DKK3 could stimulate differentiation of Sca1 + (stem cells antigen 1) vascular progenitor cells present within the adventitia of vessels, 10 as well as directly differentiate fibroblasts to SMCs. Moreover, we exogenously delivered DKK3 in vivo and showed that DKK3 may have the potential to prevent plaque rupture in rabbit models. Finally, detecting the levels of DKK3 in the serum of patients with stable or unstable angina revealed that DKK3 may be important for vascular homeostasis.
A therosclerosis is a progressive inflammatory disease of the arterial wall that can be clinically silent for many years before triggering acute episodes such as myocardial infarctions or strokes. 1 The condition is generally characterized by the accumulation of cholesterol, macrophage infiltration, smooth muscle cell (SMC) proliferation, connective tissue accumulation, and thrombus formation. 2, 3 During the early stages of atherosclerosis, thin fatty streaks develop in the arterial wall because of endothelial cell (EC) damage. Deposition of materials, such as lipids, and the proliferation of underlying cells, such as SMCs, lead to the generation of advanced lesions known as atherosclerotic plaques, which contain fibrous caps of variable thickness. In humans, atherosclerotic plaques with a thin fibrous cap are unstable and likely to rupture, causing acute coronary syndromes. 4 
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Mice deficient in ApoE (apolipoprotein E) are appropriate models for tracking the development of advanced lesions and are used in most genetic and physiological studies. 5 A model of atherosclerotic plaque in ApoE −/− mice subjected to tandem stenosis of the carotid artery has recently been developed, in which characteristics such as intraplaque hemorrhage and intraluminal thrombosis, events similarly seen in human unstable plaques, are observed. 6 This model is considered a suitable tool for testing therapeutic strategies toward changing plaque phenotype. February 2018
We have previously shown that DKK3, a member of the dickkopf family of Wnt inhibitors, 7 is involved in the differentiation of partially induced pluripotent stem cells 8 and embryonic stem cells 9 to SMCs. Consequently, assessing the therapeutic potential of DKK3, possibly through differentiation of stem/progenitor cells to SMCs, deemed crucial. Hence, in this study, we used the aforementioned animal model in conjunction with DKK3 −/− mice and found that DKK3 −/− ApoE −/− mice presented with vulnerable plaques. In addition, using in vitro differentiation protocols, we found that DKK3 could stimulate differentiation of Sca1 + (stem cells antigen 1) vascular progenitor cells present within the adventitia of vessels, 10 as well as directly differentiate fibroblasts to SMCs. Moreover, we exogenously delivered DKK3 in vivo and showed that DKK3 may have the potential to prevent plaque rupture in rabbit models. Finally, detecting the levels of DKK3 in the serum of patients with stable or unstable angina revealed that DKK3 may be important for vascular homeostasis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

DKK3 Effects Plaque Composition and Not Lesion Size
To assess the effects of DKK3 on plaque formation and composition, a previously described murine atherosclerotic plaque model 12, 13 . We thus concluded that although DKK3 could exert an effect on plaque phenotype, it has no effect on the number or size of plaques developed.
To further establish the role of DKK3 in plaque composition, assessment of plaque rupture of a vein graft model in DKK3 −/− ApoE −/− mice was used as previously described. 14, 15 Vein graft rupture complications were scored in 10 mice in each group. Erythrocytes were found adjacent to neovessels of lesions in all animals of the DKK3 −/− ApoE −/− group. Dissection, necrosis and calcification coinciding with erythrocytes, was defined as erosion with intramural thrombosis (Figure 2 ). Moreover, cell composition analysis of the plaques exhibited decreased SMCs and increased CD68 + macrophages in the DKK3 −/− ApoE −/− group, which coincided with decreased matrix proteins in lesions (Figure VI in the online-only Data Supplement) indicating that absence of DKK3 significantly enhanced plaque rupture complications in vein graft models.
Vascular Progenitors and Fibroblasts Migrate to the Intima In Vivo
While investigating the effects of DKK3 on plaque composition, it became apparent that DKK3 expression positively correlates with the presence of SMCs within the plaque. We have previously shown that Sca1 + vascular progenitor cells can differentiate into SMCs in vitro. 16 It was therefore interesting to explore whether this increase was related to vascular progenitor migration and differentiation. Immunostaining for Sca1 was performed on sections of atherosclerotic plaques, 8 weeks after tandem stenosis surgery. The presence of Sca1 Using the wire injury model, Sca1
+ progenitors and fibroblasts were isolated from SM22-LacZ (smooth muscle protein 22-β-galactosidase) transgenic mice and seeded on the adventitia of a wild-type mouse after femoral artery injury. En face staining and β-gal development revealed that both SM22-LacZ progenitors and SM22-LacZ fibroblasts migrated to the intima of the injured vessel and differentiated into SMCs ( Figure VIIID in the online-only Data Supplement).
DKK3 Can Induce Differentiation of Fibroblasts to SMCs In Vitro
The effects of DKK3 on plaque composition prompted the investigation of the potential of DKK3 to induce fibroblastto-SMC differentiation in vitro. Human fibroblasts were seeded on a gelatin substrate and infected with null or DKK3 adenovirus under differentiation conditions. Initial observations of cells overexpressing DKK3 after 4 days in differentiation medium revealed a morphological SMClike change ( Figure 3A ). This correlated with upregulation of SMC markers as seen by quantitative polymerase chain reaction, in particular of SMMHC (smooth muscle myosin heavy chain) and myocardin, genes important for the contractile function of SMCs ( Figure 3B ). Furthermore, an increase in the expression of elastin and collagen, markers characteristic of terminally differentiated SMCs, was noted. These results were confirmed at the protein level by Western blot ( Figure 3C ) and immunofluorescence ( Figure 3D ). ELISA confirmed that on overexpression of DKK3, there is an increased release of DKK3 cytokine in the supernatant ( Figure 3E ). As expected, DKK3 overexpression increased the levels of collagen at the mRNA and protein levels. In turn, this led to an increased secretion in the supernatant ( Figure 3F ). Finally, to establish whether an SMC program was initiated, we assessed the promoter activity levels of the SMC markers myocardin and SMMHC. Luciferase promoter assays revealed an increase in promoter activity of both myocardin and SMMHC on overexpression of DKK3 in differentiation medium conditions ( Figure 3G and 3H). Thus, it can be concluded that DKK3 can drive differentiation of fibroblasts into SMCs under defined culture conditions where the generated cells exhibit a clear SMC transcriptional program and behave like terminally differentiated SMCs.
Fibroblast Differentiation to SMCs on DKK3 Overexpression Is Mediated by TGF-β1 Induction and Generates Functional SMCs
After establishing DKK3-induced fibroblast-to-SMC differentiation, we investigated the mechanism by which this transformation occurs. As TGF-β1 (transforming growth factor-β1) has previously been associated with SMC differentiation, 17 an ELISA was performed to detect possible changes in the extracellular levels of TGF-β1 of DKK3-overexpressing fibroblasts. Indeed, it was found that there was an increased release of TGF-β1 on DKK3 overexpression ( Figure 4A ). To better understand the potential relationship between DKK3 and TGF-β1, fibroblasts were stimulated with human recombinant TGF-β1 with or without DKK3 overexpression and compared with untreated cells. Initial observations in cell morphology revealed that the cells treated with a combination of TGF-β1 and DKK3 were distinctly different from untreated fibroblasts and fibroblasts treated with TGF-β1 alone ( Figure IXA in the online-only Data Supplement). In addition, quantitative polymerase chain reaction analysis revealed that on TGF-β1 stimulation, cells overexpressing DKK3 expressed SMC markers and components of the ECM at higher levels ( Figure 4B ). These results were confirmed at the protein level ( Figure IXB in the online-only Data Supplement). To further establish the cooperative effect of DKK3 and TGF-β1, a specific inhibitor of the receptor for TGF-β1 (ALK5) was used in DKK3-overexpressing fibroblasts. On inhibition of ALK5, there was a striking ablation of SMC marker expression ( Figure 4C ; Figure IXC in the online-only Data Supplement). Furthermore, a neutralizing antibody specifically inhibiting active TGF-β1 was used in the culture medium, which revealed an inhibition of SMC marker expression ( Figure IXD and IXE in the online-only Data Supplement). To confirm that the simultaneous presence of DKK3 and TGF-β1 is indispensable for the induction of SMC markers, fibroblasts were stimulated by TGF-β1 in the presence (NT [non targeting] lentivirus) or absence (shDKK3) of DKK3. It was revealed that on silencing of DKK3, there was a dramatic abrogation of the expression of SMC markers and ECM components ( Figure 4D ; Figure  IXF in the online-only Data Supplement). Finally, the endogenous expression of TGF-β1 was silenced using a lentivirus. As shown in Figure IXG and IXH in the onlineonly Data Supplement, the expression of SMC markers and matrix components was inhibited, indicating a repression of the SMC differentiation program.
Having established the existence of a synergistic effect between DKK3 and TGF-β1, it was interesting to study whether DKK3 was transcriptionally regulating the de novo synthesis of TGF-β1. Initially, quantitative polymerase chain reaction ( Figure 4E ) and Western blot analysis ( Figure  XA in the online-only Data Supplement) revealed that there was an increased expression of TGF-β1 on DKK3 overexpression, whereas knockdown of DKK3 resulted in decrease of TGF-β1 and pSmad2 at the protein level ( Figure 4F ). Furthermore, increased levels of TGF-β1 activated the downstream signaling pathway as indicated by Smad phosphorylation (Figure XB in the online-only Data Supplement). Finally, to identify the mediator of TGF-β1 induction in our system, we investigated whether a transcription factor could regulate de novo TGF-β1 transcription. After using A, Phase contrast images depicting the morphological differences between human fibroblasts infected with null and hDKK3 adenovirus while cultured in differentiation medium (DM) for 4 days. B, Quantitative polymerase chain reaction (Q-PCR) for SMC markers (mean±SEM of n=3; *P<0.05) and confirmation at the protein level by (C) Western blot analysis (n=4) and (D) immunofluorescent staining. ELISA immunoassays were used to assess the levels of (E) DKK3 and (F) Coll1A1 (collagen 1A1) secreted in the supernatant (mean±SEM of n=3; ***P<0.001). Activation of the SMC specific promoters (G) Myocardin and (H) SMMHC (smooth muscle myosin heavy chain) as determined by using a luciferase promoter assay on overexpression of hDKK3 (mean±SEM of n=3; *P<0.05).
the Qiagen Champion ChiP Transcription Factor Search Portal, we found that the transcription factor ATF6 (activating transcription factor 6) was upregulated up DKK3 overexpression ( Figure 4G ; Figure XC in the online-only Data Supplement). To confirm whether DKK3 was inducing ATF6 expression, fibroblasts were infected with NT or shDKK3 during differentiation. We found that on DKK3 silencing, ATF6 expression was also reduced, indicating that its expression is regulated by DKK3 ( Figure 4H ; XD in the online-only Data Supplement). Moreover, siATF6 led to a decrease in TGF-β1 at both RNA and protein levels (Figure X in the online-only Data Supplement; Figure 4I ), whereas ATF6 overexpression not only upregulated TGF-β1 but also led to an increased expression of a full panel of SMC markers and ECM components ( Figure 4J ). We therefore concluded that on DKK3 overexpression, the transcription factor ATF6 is upregulated and in turn causes the transcriptional upregulation of TGF-β1, which ultimately leads to the induction of SMC markers in fibroblasts.
We then went on to assess the functionality of DKK3-generated SMCs. An in vitro contractility assay was used to prove the contractile ability of said SMCs (Movie I in the onlineonly Data Supplement). In addition, a Matrigel plug assay was used to examine their ability to generate functional vessels in vivo when mixed with human umbilical vein ECs. DKK3-induced SMCs were labeled with a red cell tracker (QTracker red), mixed with HUVECs (human umbilical vein endothelial cells) in Matrigel, and then injected subcutaneously into SCID (severe combined immunodeficiency) mice. Samples were obtained after 2 weeks, and sections were stained with hematoxylin/eosin. It was observed that these cells had the ability to form complete vessels characteristic of the vessels formed when mixing functional SMCs and ECs in vivo ( Figure 4K ). Immunofluorescent staining of frozen sections for EC markers ( Figure 4L and 4M) revealed that although ECs formed tubular structures comprising the inner lining of vessels, the induced SMCs ( Figure 4N ) correctly positioned on the outside layer, enveloping the EC tubes and forming robust 2 layer vessels. We thus concluded that DKK3 can induce the differentiation of functional SMCs capable of forming complete vessels in vivo.
Sca1
+ Progenitors Can Differentiate to SMCs via DKK3 and Activation of the Wnt Signaling Pathway
Establishing the effects of DKK3 on fibroblast-to-SMC differentiation and identifying the differentiation of Sca1 + cells to SM22 + on transplantation in a mouse femoral artery lead to in vitro investigation of the role of DKK3 in the differentiation of Sca1 + cells to SMCs. Sca1 + cells were seeded on a collagen IV substrate and maintained in differentiation medium for 6 days as previously described. 16 Analysis of the samples harvested displayed an upregulation of SMC markers accompanied by an upregulation of DKK3 ( Figure 5A and 5B). In addition, ELISA revealed that there was an increasing release of DKK3 in the supernatant during differentiation toward SMCs ( Figure 5C ). Immunofluorescent staining of differentiated cells revealed characteristic SMC marker staining parallel to an increase in DKK3 staining ( Figure 5D ). Interestingly, silencing of DKK3 using shDKK3 led to a downregulation of SMC markers ( Figure 5E and 5F). Neutralization of secreted DKK3 by utilization of a DKK3 antibody also revealed a downregulation of SMC marker expression ( Figure 5G and 5H). To further confirm the role of DKK3 in Sca1 + cell differentiation, cells were stimulated with recombinant DKK3. Western blot analysis ( Figure 5I and 5J) indicated a further induction of SMCs markers on stimulation with exogenous DKK3. Finally, adenoviral overexpression of DKK3 in differentiating Sca1
+ cells led to further induction of SMC markers ( Figure 5K and 5L). Establishing DKK3 involvement in Sca1 + cell differentiation to SMCs led to investigation of the mechanism by which this effect occurs. It has been shown that DKK3 is involved in the differentiation of partially induced pluripotent stem cells into SMCs. 18 We therefore investigated whether this was the case in this system. Initially, an anti-DKK3 antibody was used to neutralize the effect of DKK3 in the supernatant of differentiating Sca1 Figure 6A through 6C) . In addition, sections were immunostained with anti-SMA antibody. Interestingly, DKK3 treatment resulted in increased numbers of SMCs within the plaque, comparable to those found within the control animals ( Figure 6D through 6F) . Similarly, sections were immunostained for CD68 and exhibited a similar macrophage infiltration between DKK3-treated and DKK3-untreated animals ( Figure 6G through 6I) . Finally, Miller and Picosirius staining exhibited a similar deposition of ECM proteins between the 2 groups ( Figures 6J through 6L) . Hence, these results indicate that exogenous DKK3 can successfully change the composition of atherosclerotic plaques by reducing intraplaque hemorrhage, increasing SMC and ECM deposition and reduced macrophage infiltration.
Administration of DKK3 Adenovirus Alters Atherosclerotic Plaque Phenotypes in Rabbits
The transforming effects of DKK3 on ApoE −/− mouse plaques prompted for further investigation in a larger animal model. New Zealand White rabbits were subjected to a balloon-induced aortic wall injury and fed on a high-fat diet to trigger development of atherosclerotic plaques. They then received a suspension of either adeno-vector (control) or DKK3 adenovirus at weeks 12, 14, 16, and 18 and were euthanized at week 20. ELISA detection of DKK3 in the serum of both groups revealed that from week 12 onward, the levels of released DKK3 in the serum were consistently higher in the adeno-DKK3-infected rabbits when compared with the controls revealing successful overexpression ( Figure XIII in the online-only Data Supplement). Immunostaining of sections with anti-SMA antibody indicated a significant increase of SMCs numbers within the plaques of subjects injected with DKK3 adenovirus when compared with control subjects (Figure 7A through 7C) . In addition, sections were immunostained for RAM11, where it was found that animals infected with adeno-DKK3 exhibited a lower macrophage infiltration ( Figure 7D through  7F) . Similarly, cells were immunostained for MMP9 (matric metallopeptidase 9), a metalloproteinase involved in the degradation of the ECM. Sections obtained from the adeno-DKK3 rabbits presented with fewer MMP9
+ cells compared with the control group ( Figure 7G through 7I) . Finally, immunostaining of sections for elastin and collagen showed that there was an increased accumulation of ECM in rabbit plaques treated with DKK3 versus the control group ( Figure 7J through 7L) . Notably, in terms of blood lipid profile and lesional areas in rabbit aorta, oil red O staining indicated no significant difference between the adeno-DKK3 and control groups (Figures V and XIV in the online-only Data Supplement). Taken together, we conclude that DKK3 exhibits a plaque stabilizing effect in rabbit atherosclerotic plaques by increasing SMC presence and matrix protein deposition and by reducing macrophage infiltration within the plaque.
Decreased DKK3 Levels in Patients With Unstable Angina
We previously described secretion of DKK3 from cells, including platelets, which could be measured in the serum. Because unstable plaques are difficult to diagnose in patients, we selected patients with unstable and stable angina symptoms, which may indirectly reflect to the status of atherosclerosis. Sera were collected from patients, with or without unstable angina and were analyzed for DKK3 by ELISA. As listed in Table II in the online-only Data Supplement, subjects from both groups were matched for age, sex, and body mass index. Subjects did not differ in blood pressure, total cholesterol, LDL (low-density lipoprotein), and HDL (highdensity lipoprotein) cholesterol. DKK3 levels were inversely correlated with unstable angina (P<0.05; Figure 8 ; Table II in the online-only Data Supplement). These pilot data suggest that serum DKK3 levels might be important for vascular hemostasis.
Discussion
The main cause of acute coronary syndromes of unstable angina, myocardial infarction, and sudden death is plaque disruption with superimposed thrombosis, and coronary atherosclerosis is undoubtedly the most frequent cause of ischemic heart disease. 19, 20 Over the years, it has been established that the composition and vulnerability of the plaque rather than its volume or the consequent severity of stenosis are important determinants for the development of acute coronary syndromes because soft unstable plaques are rupture-prone and highly thrombogenic after disruption when compared with collagen-rich hard plaques. 21 Clinical observations show that stabilizing plaques may be of great therapeutic significance and that plaque stabilization may be an approach to convey clinical stability. 22, 23 In the present study, we have used a tandem stenosis model, 13 vein graft, and rabbit models of atherosclerotic plaques and have investigated the therapeutic potential of DKK3 in altering plaque composition. Although DKK3 has been associated with cancer as a potent tumor suppressor, 24, 25 recent studies suggest that its role might extend to an association with cardiovascular pathologies 26, 27 and transformation toward vascular lineages, specifically SMCs. 9, 18 Our initial observations suggested that the absence of DKK3 resulted in more vulnerable plaques. These results indicated that the presence of DKK3 within the plaques was promoting plaque alterations while correlating with high numbers of SMCs and ECM deposition, which prompted further investigation in vitro and in vivo.
Recently, Cheng et al 28 demonstrated that loss of DKK3 attenuates atherosclerosis in ApoE null mice fed with high-fat diet through the activation of β-catenin signaling. Interestingly, Yu et al 29 reported that DKK3 is atheroprotective from human population study and mouse models, in which the mechanism seems not involving in β-catenin signaling. In our view, the conflicting data published in the literature might be because of the differences in the animal models, that is, high-fat diet (Cheng et shown that mesenchymal stem cell-like cells in the adventitia are progenitors of vascular SMCs and contribute to neointima formation and repair after acute injury to the femoral artery. 32 Similarly, reports indicate that the fibroblasts present within the adventitia can directly contribute to SMC accumulation in animal models. 33, 34 Using the tandem ligation stenosis model, we have found the presence of Sca1 + progenitors within the plaques. In conjunction with the plaque stability model, we have demonstrated that the application of vascular progenitors and fibroblasts to the adventitia can cause these cells to migrate toward the intima of the vessel and differentiate toward SMCs. This supports the involvement of vascular progenitors in plaque composition change, despite the lack of direct evidence of the contribution to SMC accumulation in the lesion. Certainly, the generation of a cell lineage-tracing model that would accurately display the contribution of progenitor cell differentiation toward different cell lineages or fibroblasts to plaque formation would strengthen the present data. Although we have previously found that DKK3 is involved in SMC differentiation, 18 the protocol that we established required the cells to go through a short period of reprogramming using the 4 reprogramming factors used by Okita et al. 35 Here, however, we investigated the potential of DKK3 to directly reprogram fibroblasts to SMCs through a simple and efficient differentiation process under defined adenoviral culture conditions. During this process, not only did we establish differentiation of fibroblasts to SMCs, but we also generated a protocol by which DKK3 can induce an abundant population to differentiate into SMCs that can be used in personalized regenerative cell therapy. Investigation into the mechanism behind this differentiation shows that DKK3 leads to the activation of the transcription factor ATF6 ( Figure XV in the online-only Data Supplement). These results are in agreement with previously published data, where ATF6 induced differentiation of embryonic stem cells into SMCs via regulation of the SMC master transcription factor myocardin. 9 Taking into consideration that DKK3 can induce differentiation of Sca1 + progenitors into SMCs, we can safely assume that it can be considered an SMC regulator gene that activates an SMC differentiation program in different cells, ranging from terminally differentiated to pluripotent cells.
The results obtained encouraged for further investigation into the therapeutic potential of DKK3 in shifting plaque composition. A variety of approaches such as elevation of HDL 36 and dietary fatty acids 37 have previously been used to alter plaque composition and possibly stabilize it. It would therefore be interesting to use a plaque stability model of rabbits to assess the positive effects of DKK3 in altering plaque composition. Excitingly, treatment of DKK3 −/− ApoE −/− animals with exogenous recombinant DKK3 increased matrix protein in plaque to levels comparable with wild-type ApoE −/− mice. It should be noted that the plaques of the DKK3-treated group present with a higher number of SMCs resulting in an increase of ECM, a characteristic of hard stable plaques. In addition, the diminished macrophage infiltration within the plaque suggests a potential anti-inflammatory effect of DKK3 worth further study. Most importantly, the stabilizing effect of DKK3 was demonstrated in a rabbit model of atherosclerosis and vessel injury, exhibiting all the aforementioned effects including a significant reduction in MMP9 expression. During atherosclerosis, metalloproteinases play an active role in degrading the matrix proteins and promoting vascular remodeling. 38 Our data suggest that DKK3 not only promotes matrix accumulation within plaques but also inhibits further degradation of the matrix proteins and ultimately vascular remodeling.
In summary, we have established the positive effects of DKK3 on atherosclerotic plaque using several animal models and humans. We have established that DKK3 can promote these effects, via inducing differentiation of vascular progenitors and fibroblasts into functional SMCs and generated a novel protocol for directly differentiating fibroblasts to SMCs in vitro. In addition, we used a mouse model of plaque and a rabbit injury model to establish the therapeutic potential of DKK3 and found that it can successfully promote plaque stabilization in both models. Interestingly, patients with unstable angina displayed a lower level of serum DKK3. We therefore present a collection of evidence that DKK3 is a potent SMC differentiation factor that might be an excellent therapeutic agent toward reducing acute hemorrhagic conditions such as myocardial infarction and stroke. 
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